Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity von Bachmetov, L., Gal-Tanamy, M., Shapira, A., Vorobeychik, M., Giterman-Galam, T., Sathiyamoorthy, P., Golan-Goldhirsh, A., Benhar, I., Tur-Kaspa, R., Zemel, R.

Volltext

Mutations in ERGIC1 cause Arthrogryposis multiplex congenita, neuropathic type von Reinstein, E., Drasinover, V., Lotan, R., Gal‐Tanamy, M., Bolocan Nachman, I., Eyal, E., Jaber, L., Magal, N., Shohat, M.

Volltext

822 VITAMIN-D ACTIVATES INNATE IMMUNITY AGAINST HCV AND INHIBITS VIRAL PRODUCTION von Bachmetov, L, Gal–Tanamy, M, Ravid, A, Koren, R, Erman, A, Zemel, R, Tur-Kaspa, R

Volltext

740 INHIBITION OF HCV NS3 SERINE PROTEASE BY THE FLAVANOID QUERCETIN von Bachmetov, L, Zemel, R, Gal-Tanamy, M, Vorobeychik, M, Benhar, I, Tur-Kaspa, R

Volltext

773 SINGLE-CHAIN ANTIBODIES INHIBIT HCV INFECTIOUS VIRUS REPLICATION BY PROTEIN DELIVERY von Giterman-Galam, T, Gal-Tanamy, M, Bachmatov, L, Yi, M, Lemon, S.M, Benhar, I, Zemel, R, Tur-Kaspa, R

Volltext

HCV NS3 Serine Protease-neutralizing Single-chain Antibodies Isolated by a Novel Genetic Screen von Gal-Tanamy, Meital, Zemel, Romy, Berdichevsky, Yevgeny, Bachmatov, Larissa, Tur-Kaspa, Ran, Benhar, Itai

Volltext

345 INHIBITION OF HCV CELL CULTURE INFECTIOUS VIRUS AND DRUG RESISTANT REPLICONS BY INTRABODIES von Gal-Tanamy, M, Zemel, R, Bachmetov, L, Jangra, R, Villanueva, R, Yi, M, Lemon, S, Benhar, I, Tur-Kaspa, R

Volltext

SAT-427 - Development and characterization of unique hepatitis C virus neutralizing antibodies associated with infection outcome von Baran, S.E., Eliyahu, S., Davidovich, A., Brown, M., Gal-Tanamy, M., Nimer, A.

Volltext

Development and characterization of unique hepatitis C virus neutralizing antibodies associated with infection outcome von Baran, S.E., Eliyahu, S., Davidovich, A., Brown, M., Gal-Tanamy, M., Nimer, A.

Volltext

Inhibition of hepatitis C virus RNA replicons by peptide aptamers von Trahtenherts, Alla, Gal-Tanamy, Meital, Zemel, Romy, Bachmatov, Larisa, Loewenstein, Shelly, Tur-Kaspa, Ran, Benhar, Itai

Volltext

P640 Serologic response and safety after third dose of the COVID-19 BNT162b2 vaccine in patients with Inflammatory Bowel Diseases von Edelman-Klapper, H, Rabinowitz, K M, Zittan, E, Bar-Gil Shitrit, A, Goren, I, Avni-Biron, I, Ollech, J E, Lichtenstein, L, Banai-Eran, H, Yanai, H, Snir, Y, Pauker, M H, Friedenberg, A, Levy-Barda, A, Segal, A, Broitman, Y, Maoz, E, Ovadia, B, Aharoni Golan, M, Shachar, E, Ben-Horin, S, Mor, M, Ben Zvi, H, Perets, T T, Eliakim, R, Barkan, R, Navon, M, Gal-Tanamy, M, Freund, N T, Goren, S, Cohen, D, Dotan, I

Volltext

Hepatitis C virus leaves epigenetic signature post cure by direct-acting antivirals that is linked to distinct mutation signature von Gal-Tanamy, M., Perez, S., Lavi-Itzkovitz, A., Kaspi, A., Davidovich, A., Tobar, A., Livoff, A., Nimer, A., Solomonov, E., El-Osta, A., Yaari, G., Stemmer, S.M., Haviv, I.

Volltext

PS-120 - Hepatitis C virus leaves epigenetic signature post cure by direct-acting antivirals that is linked to distinct mutation signature von Gal-Tanamy, M., Perez, S., Lavi-Itzkovitz, A., Kaspi, A., Davidovich, A., Tobar, A., Livoff, A., Nimer, A., Solomonov, E., El-Osta, A., Yaari, G., Stemmer, S.M., Haviv, I.

Volltext

P313 Within, 6 months from COVID-19 BNT162b2 vaccine patients with Inflammatory Bowel Diseases treated with Anti-TNFα have significantly lower serologic responses von Rabinowitz, K M, Navon, M, Edelman-Klapper, H, Zittan, E, Bar-Gil Shitrit, A, Goren, I, Avni-Biron, I, Ollech, J E, Lichtenstein, L, Banai-Eran, H, Yanai, H, Snir, Y, Pauker, M H, Friedenberg, A, Levy-Barda, A, Segal, A, Broitman, Y, Maoz, E, Ovadia, B, Aharoni Golan, M, Shachar, E, Ben-Horin, S, Perets, T T, Ben Zvi, H, Eliakim, R, Barkan, R, Goren, S, Krugliak, N, Werbner, M, Alter, J, Dessau, M, Gal-Tanamy, M, Cohen, D, Freund, N T, Dotan, I

Volltext

59 Anti-HCV NS3 serine protease intrabodies act in an unusual inhibition mechanism and have an additive inhibitory effect with IFN-α von Gal-Tanamy, M., Zemel, R., Pupko, O., Yi, M., Bachmatov, L., Denisova, G., Gershoni, J.M., Lemon, S.M., Benhar, I., Tur-Kaspa, R.

Volltext

396 Hepatitis C virus NS3 serine protease-neutralizing single-chain antibodies; isolation and characterization von Gal-Tanamy, M., Ben-Zeev, E., Zemel, R., Bachmatov, L., Berdichevsky, Y., Eisestein, M., Benhar, I., Tur-Kaspa, R.

Volltext

The unique inhibition mechanism of intrabodies against hepatitis C virus serine protease and their additive effect with IFN-alpha von Gal-Tanamy, M, Zemel, R, Pupko, O, Bachmatov, L, Yi, M, Denisova, G, Gershoni, J M, Lemon, S M, Benhar, I, Tur-Kaspa, R

Volltext

O.080 The unique inhibition mechanism of intrabodies against hepatitis C virus serine protease and their additive effect with IFN-alpha von Gal-Tanamy, M., Zemel, R., Pupko, O., Bachmatov, L., Yi, M., Denisova, G., Gershoni, J.M., Lemon, S.M., Benhar, I., Tur-Kaspa, R.

Volltext

Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals von Perez, Shira, Kaspi, Antony, Domovitz, Tom, Davidovich, Ateret, Lavi-Itzkovitz, Anat, Meirson, Tomer, Alison Holmes, Jacinta, Dai, Chia-Yen, Huang, Chung-Feng, Chung, Raymond T, Nimer, Assy, El-Osta, Assam, Yaari, Gur, Stemmer, Salomon M, Yu, Ming-Lung, Haviv, Izhak, Gal-Tanamy, Meital

Volltext

Definition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal Antibodies von KECK, Zhen-Yong, LI, Ta-Kai, JINMING XIA, GAL-TANAMY, Meital, OLSON, Oakley, LI, Sophia H, PATEL, Arvind H, BALL, Jonathan K, LEMON, Stanley M, FOUNG, Steven K. H

Volltext